Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected

This article was originally published in The Pink Sheet Daily

Executive Summary

Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.
Advertisement

Related Content

EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track
Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight

Topics

Advertisement
UsernamePublicRestriction

Register

PS071749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel